4CPS-233 PD-l1 expression and histological type as predictors of response in metastasic non-small-cell lung cancer (NSCLC) patients treated with pembrolizumab in first-line

Abstract

Background and ImportanceIn patients with NSCLC and programmed death ligand-1 (PD-L1) expression ≥50%, pembrolizumab as first-line treatment has shown an increase in survival over platinum-based chemotherapy. To date, it is...